- Home
- ESTA vs NVAX Comparison
ESTA vs NVAX Comparison
Compare ESTA & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTA
- NVAX
- Stock Information
- Founded
- ESTA 2004
- NVAX 1987
- Country
- ESTA Costa Rica
- NVAX United States
- Employees
- ESTA N/A
- NVAX N/A
- Industry
- ESTA Industrial Specialties
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESTA Health Care
- NVAX Health Care
- Exchange
- ESTA Nasdaq
- NVAX Nasdaq
- Market Cap
- ESTA 1.4B
- NVAX 1.4B
- IPO Year
- ESTA 2018
- NVAX 1995
- Fundamental
- Price
- ESTA $49.28
- NVAX $8.54
- Analyst Decision
- ESTA Strong Buy
- NVAX Hold
- Analyst Count
- ESTA 5
- NVAX 6
- Target Price
- ESTA $55.40
- NVAX $11.33
- AVG Volume (30 Days)
- ESTA 350.7K
- NVAX 4.7M
- Earning Date
- ESTA 11-05-2025
- NVAX 11-11-2025
- Dividend Yield
- ESTA N/A
- NVAX N/A
- EPS Growth
- ESTA N/A
- NVAX N/A
- EPS
- ESTA N/A
- NVAX 2.54
- Revenue
- ESTA $177,418,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- ESTA $28.32
- NVAX $61.25
- Revenue Next Year
- ESTA $23.92
- NVAX N/A
- P/E Ratio
- ESTA N/A
- NVAX $3.35
- Revenue Growth
- ESTA 17.22
- NVAX 9.22
- 52 Week Low
- ESTA $26.56
- NVAX $5.01
- 52 Week High
- ESTA $51.34
- NVAX $11.55
- Technical
- Relative Strength Index (RSI)
- ESTA 70.45
- NVAX 49.96
- Support Level
- ESTA $47.09
- NVAX $8.19
- Resistance Level
- ESTA $51.34
- NVAX $8.83
- Average True Range (ATR)
- ESTA 2.43
- NVAX 0.44
- MACD
- ESTA 0.77
- NVAX -0.07
- Stochastic Oscillator
- ESTA 85.96
- NVAX 35.44
About ESTA Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.